Laxmi Organic Industries Limited reported a consolidated net profit of ₹793.62 million for the financial year ended March 31, 2026, a decrease from ₹1,135.04 million in the previous year. Revenue from operations for the year stood at ₹28,466.67 million, down from ₹29,854.42 million in FY25. For the quarter ended March 31, 2026, the company posted a consolidated net profit of ₹215.51 million.

The Board of Directors has recommended a final dividend of ₹0.30 per equity share of face value ₹2 each for FY26, amounting to 15% of the face value. This dividend is subject to the approval of shareholders at the ensuing 37th Annual General Meeting. The Board has fixed Tuesday, July 21, 2026, as the record date to determine shareholder eligibility for the dividend.

Key Financial Metrics

The company’s standalone net profit for FY26 was ₹792.58 million, compared to ₹1,180.21 million in the previous year. Standalone revenue from operations for the year was ₹28,085.32 million. Total comprehensive income for the consolidated entity for the year was ₹788.15 million.

Operational and Board Updates

The Board approved the re-appointment of M/s B. J. D. Nanabhoy & Company, Cost Accountant, as the Cost Auditor for the financial year 2026-27, subject to ratification by shareholders. Additionally, the Board approved the appointment of Mr. Amit Jain as the Chief Financial Officer and Key Managerial Personnel, effective from the commencement of business hours on June 16, 2026. Consequently, Mr. Harshvardhan Goenka, Executive Director, will cease to hold the responsibilities of Interim Chief Financial Officer from the close of business hours on June 15, 2026.

The statutory auditors, Deloitte Haskins & Sells LLP, issued an unmodified opinion on the audited standalone and consolidated financial results for the year ended March 31, 2026. The Board also approved the convening of the 37th Annual General Meeting on Wednesday, August 5, 2026, via Video Conferencing.

Laxmi Organic Industries has filed its audited financial results for the quarter and year ended March 31, 2026, and subsequently hosted an Investor & Analyst Meet on May 22, 2026. The company reported a 4% year-on-year increase in consolidated revenue from operations to INR 7,380 Mn for Q4 FY26, compared to INR 7,108 Mn in the same period last year. For the full fiscal year FY26, revenue stood at INR 28,620 Mn, a decline of 5% from INR 30,108 Mn in FY25. The meet was hosted by Strategic Growth Advisors and conducted as a conference call, with no Unpublished Price Sensitive Information shared during the session.

Financial Performance

Profitability metrics for the quarter reflected a mixed performance. Profit After Tax (PAT) for Q4 FY26 was INR 211 Mn, a decrease of 2% from INR 215 Mn in Q4 FY25. On a full-year basis, PAT declined by 31% to INR 788 Mn from INR 1,138 Mn in the previous year. The company's EBITDA for Q4 FY26 was INR 536 Mn, down 9% YoY, with an EBITDA margin of 7.3%, a contraction of 100 basis points. For FY26, EBITDA fell 39% to INR 1,714 Mn. The following table summarises the key financial metrics across periods:

Operational Highlights

Revenue growth in Q4 was primarily driven by higher price realizations. Sequentially, the Adjusted EBITDA margin improved by 520 basis points, and revenues grew by 9% quarter-on-quarter, driven across both the Essentials and Specialties businesses. The results for FY26 included one-time items: a gain of INR 407 Mn from a favorable litigation settlement regarding wheeling and transmission charges, and expenses of INR 38 Mn related to the Labour Code Impact and a supply chain redesign project. Employee costs increased by approximately INR 14 crores on account of new site setups, compounded by the absence of one-time reversals that had benefited FY25.

Segment Performance

Revenue from the Essentials segment for Q4 FY26 grew 7% to INR 5,220 Mn, while the Specialties segment revenue decreased by 3% to INR 2,132 Mn. For the full year, Essentials revenue remained flat at INR 20,268 Mn, whereas Specialties revenue dropped 18% to INR 7,791 Mn. The Adjusted EBITDA contribution from the Essentials segment increased to 37% in Q4 FY26 from 33% in the previous year. Management attributed the Specialties decline to three factors: the structural loss of one large contract (approximately 10% of top line), deferment of shipments by key customers from the first half to the second half of the year, and a deflationary feedstock environment where acetic acid prices dropped close to 30% over a two-year period.

Macro Environment and Raw Material Trends

Dr. Rajan Venkatesh, MD & CEO, highlighted significant macro headwinds during the earnings call. Acetic acid prices, which had fallen to approximately $300–$320 levels earlier, recovered to above $400 in Q3, moderated to $350–$370 in January–February, and then spiked sharply to beyond $700 in March–April due to the Middle East conflict and its impact on methanol supply. Prices have since moderated to approximately $450–$470. Ethyl acetate (ETAC) spreads, which were around $100–$110 in Q3 FY26, improved to approximately $130 in January–February, spiked to $220 in March and $250 in April, and have since moderated to $150–$160. Logistics costs have also doubled since the onset of the Middle East conflict, with multiple surcharges adding to operational headwinds.

Project Updates and New CFO Appointment

On the capital projects front, the fluorination setup at Lote achieved 40%–45% of peak revenues in FY26, with a healthy order book entering the current financial year. The company also commenced operations at its world-scale ethyl acetate setup at Lote and has begun dispatches to customers. At the Dahej facility, Phase 1 is operational and supplying the market, while Phase 2 chemical charging is scheduled for Q1 FY27, with revenues expected to impact the P&L positively in the second half of FY27. The supply chain digitization project is expected to go live in Q2 FY27. Additionally, Laxmi Organic announced the appointment of Mr. Amit Jain as Chief Financial Officer, effective June 16. Jain joins from Gharda Chemicals, where he served as CFO, and brings 30 years of experience across chemicals, packaging, and pharmaceutical industries, spanning corporate strategy, Investor Relations, treasury, restructuring, M&A, and enterprise transformation.